CDH3 is altered in 0.02% of breast carcinoma patients [3].

CDH3 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDH3 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

CDH3 is altered in 0.08% of colorectal carcinoma patients [3].

CDH3 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDH3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDH3 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDH3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDH3 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDH3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDH3 is altered in 0.01% of malignant solid tumor patients [3].

CDH3 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CDH3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

CDH3 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDH3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].